Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.